If the Hasle and co-workers list was meant to include both myelodysplastic and myeloproliferative diseases in children, then they should have mentioned several other myeloproliferative disorders that have been reported in children.
The CCC is a classification system and not just a scoring system as the author indicated. It is unique to children as it takes into consideration the underlying condition, cytology and cytogenetics. Besides, the CCC system easily classified all pediatric cases of MDS that were not classifiable by other systems. Its utility will need to be tested in a prospective way.
In order to better categorize the chronic myeloid disorders, there is now a major need for a classification system for pediatric MPS. This will hopefully completely solve the confusion between MDS and MPS in children. The purpose of our paper 1 was to emphasize problems applying the WHO classification of myelodysplastic syndrome (MDS) 2 in children, and to propose modifications of that classification, which were useful in pediatrics while retaining the basic similarity to the original WHO classification. Gassas et al 3 criticize us for not differentiating myeloproliferative disorders (MPDs) from MDS in our paper. It was not our intention to present a comprehensive list of MPDs observed in children; therefore, we did not include CML, CNL, eosinophilic leukemia, etc., where the WHO classification is useful in children. We clearly stated, in our paper, 1 that juvenile myelomonocytic leukemia (JMML) is a separate disorder and should not be included as MDS. JMML should also not be placed under the heading of MPD because of shared features with MDS that distinguish it from MPD. It is logically grouped with similar diseases such as chronic myelomonocytic leukemia and Ph(À) CML as myelodysplastic/myeloproliferative diseases, as in the WHO classification.
We are criticized for including the transient MPD seen in Down syndrome (DS) in an MDS classification. We agree that the transient MPD in DS should not be considered as MDS; in contrast to the CCC group, 4 we clearly segregate DS myeloid disorders in a separate group in our classification. The CCC group does not clearly distinguish MDS occurring in DS from the remainder of MDS, which does not reflect the unique biological features of DS disease. Acute myeloid leukemia seen in DS should also be kept separately and not considered with the remainder of MDS or AML. These points are stated in our paper.
Gassas et al consider the CCC system 4 a classification system. Their system includes several hundred subgroups, which makes it an extremely difficult and unwieldy system to use in clinical practice or the published literature. The CCC system provides no guidelines of how to distinguish MDS from nonclonal disorders that mimic MDS, or how to distinguish MDS from AML. The CCC system shares no commonality with the WHO classification, which is now widely used for the classification of adult MDS. The CCC system does provide a means of cataloging a variety of features found in MDS in children. However, we doubt whether the CCC system will be useful as a classification system for MDS in research or clinical practice. We continue to think our classification will. 
